| Available-for-sale financial assets, comprising the Group´s
holding af Novo Nordisk B share which has been acquired with a view to
hedging the share option obligation, cf. note 24. All the shares have been
absorbed as current assets. A gain of DKK 40 million on revaluation to market
value has been recognized in shareholders equity in 2007, and DKK 35 million
has been transferred from shareholders equity to the financial income
relating to realization of shares. In 2006 the market value has been DKK 38 million,
and DKK 21 million has been transferred to financial income. |
|
